Innovative AI-driven proteogenomic analysis company applies single cell analysis expertise to developing treatments for COVID-19
The current global health crisis demands teams to put their best tools together and act quickly. Without an effective treatment for COVID-19, new therapies targeting the SARS-CoV-2 virus are in urgent need.
Single cell sequencing technology is one of the latest scientific breakthroughs. How can this powerful platform be used to combat today’s pandemic?
Proteona has recently announced that it is leading a global alliance to develop a neutralizing antibody against coronaviruses, including SARS-CoV-2, the virus causing COVID-19. The key technology used are Proteona’s single cell analysis platform and AI data analytics.
At 10am GMT+8 April 4th, listen to Proteona CEO Dr Andreas Schmidt explain the science behind in a live interview.
Tune in at Weekend Mornings with Glenn van Zutphen, Money FM 89.3 on your radio or online!
For media queries, please contact:
Dr Andreas Schmidt
Proteona Pte. Ltd. is a new biomedical company based in Singapore, Germany, and the US that is pioneering the use of DNA barcoded antibodies to provide both proteomic and genomic information from the same single cells. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research’s (A*STAR). The platform is a comprehensive sample to answer service that enables users to phenotype cells using standard protein markers and gain a deeper understanding of cell activity based upon their gene expression profiles.